Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping
Evan W. Warner(Guardant (United States)), Alexander W. Wyatt(University of British Columbia), Kim Van der Eecken(Ghent University Hospital), Xinyi E. Chen(University of British Columbia), Nicolaas Lumen(Ghent University), Joonatan Sipola(Tampere University of Applied Sciences), Karan Parekh(University of British Columbia), Elena Schönlau(University of British Columbia), Matti Annala(Tampere University), Bram De Laere(Karolinska Institutet), Jo Van Dorpe(Ghent University Hospital), Aslı D. Munzur(University of British Columbia), Gillian Vandekerkhove(University of British Columbia), Andrew J. Murtha(University of British Columbia), Sofie Verbeke(Ghent University Hospital), Piet Ost(Ghent University Hospital), Cameron Herberts(Natera (United States)), Nicolette M. Fonseca(University of British Columbia), Elie Ritch(University of British Columbia), Edmond M. Kwan(BC Cancer Agency), Sarah W.S. Ng(University of British Columbia), Gráinne Donnellan(University of British Columbia), Amanda Wong(University of British Columbia), Cecily Q. Bernales(University of British Columbia), Kevin Beja(University of British Columbia)
Cited by 44
Related Papers
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
|JAMA Oncology|2016|384
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
|European Urology|2017|218